Search

Fascinating study, showing that cancer cells secrete antioxidants that suppress immunity. When I started in the longevity field, the free radical theory was dominant. Antioxidants were touted as anti-aging. We were among the first to criticize the free radical theory of https://t.co/SOJujOZjYn #CancerResearch #Antioxidants #Longevity #Nospecificcountriesarementionedinthetweet.

Some of the scientists I respect don't think AI will help cure cancer or solve our biggest problems. I disagree. After nearly 20 years working in AI and NLP, I could not be more hopeful about the future. I believe that accelerating scientific discovery will be the most https://t.co/8CyKSJUFZ3 #AI #CancerResearch #ScientificDiscovery #Nospecificcountriesarementionedinthetweet.

За мен новината е историческа и намирам, че не е достатъчно отразена. На 19 август 2026 г. Moderna и Merck (MSD) обявиха резултатите от мащабно клинично изпитване във фаза 3: Персонализираната mRNA ваксина срещу меланом (intismeran / mRNA-4157) в комбинация с Keytruda значително намалява риска от връщане и разпространение на рака. Това е първата mRNA противоракова ваксина, която успешно преминава късна фаза на клинични изпитвания. В проучването участваха над 1100 пациенти с висок риск за меланом (стадий IIB–IV), при които туморът е бил напълно отстранен хирургично. Комбинацията ваксина + Keytruda значително удължава времето без рецидив (recurrence-free survival) и намалява риска от поява на далечни метастази в сравнение само с Keytruda. Ваксината е напълно персонализирана - създава се специално за всеки пациент въз основа на уникалните мутации на неговия тумор. Използва се същата mRNA технология, която познаваме от ваксините срещу COVID-19. Това не е просто пореден „пробив в лабораторията“. Това е реална стъпка към нова ера в онкологията. Резултатите вече се наричат „landmark“ (исторически) от водещи онколози. Компаниите планират да подадат документи за одобрение от регулаторите в близките месеци. Ако всичко върви добре, хиляди пациенти могат да се възползват още през 2027 г. Понякога истински революции идват тихо, но променят живота на хиляди хора. #mRNAvaccine #oncology #cancerresearch

The mRNA vaccine success vs melanoma in a Phase definitive 3 randomized trial today is on top of signs of success for personalized mRNA neoantigen vaccines vs pancreatic cancer, triple negative breast cancer, and non-small cell lung cancer https://t.co/cv4iXW11mw #mRNAvaccine #CancerResearch #Immunotherapy #Nospecificcountrycodesarementionedinthetweet.

I believe AI models could eventually design end-to-end pipelines for mRNA therapeutics in both cancer and autoimmune diseases. In personalized cancer vaccines, the pipeline could look like this: Tumor WES/RNA-seq → somatic mutation identification → mutant allele expression → #AIMedicine #mRNAtherapeutics #CancerResearch #Therearenospecificcountriesmentionedinthetweetprovided.Therefore #theresponseisempty.

New @NatureMedicine paper: A pan-cancer foundation model predicts immunotherapy response and highlights the biology behind it https://t.co/hfVQc24r6w @harvardmed news: https://t.co/1w6u8cEYBK Roughly a quarter of patients with advanced cancer respond durably to immune #CancerResearch #Immunotherapy #HealthTech #Nospecificcountrycodesfound.

Prinzessin Kate und König Charles nahmen an einer emotionalen Veranstaltung im St. James’s Palace teil, um das 125-jährige Bestehen von „Cancer Research UK“ zu feiern, wo Kate in einem auffälligen roten Herzchen-Kleid auftrat und ihre eigene Krebsdiagnose von 2024 zum Anlass nahm, um den Kampf gegen die Krankheit zu unterstützen. #Krebscharity #PrinzessinKate #CancerResearchUK

Supported by over €20m from 🇨🇿 Recovery Plan @eu_next, this Centre brings together cancer research, prevention and care under one roof. Around 40% of cancer cases could be prevented. Investing in prevention & early detection gives people a stronger chance against the disease. #CancerResearch #PreventionMatters #EarlyDetection #CZ

Met with Isabel Rubio, President of @EuropeanCancer, which is advancing cancer research, treatment, care & policy. Through initiatives like the Life Science Strategy & #MissionCancer, the EU is fighting against youth cancer & funding multi-country clinical trials. https://t.co/q2IfcJo1DZ #CancerResearch #YouthCancer #EUHealth #EU

U.S. cancer centers are rapidly trying to enroll patients in an early access program for daraxonrasib, a promising new pancreatic cancer drug from Revolution Medicines, following its FDA approval for expanded access after demonstrating a significant increase in survival rates in clinical trials. #PancreaticCancer #FDAApproval #CancerResearch #US #CA #NE

U.S. cancer centers are urgently enrolling patients in an early access program for Revolution Medicines' promising pancreatic cancer drug, daraxonrasib, following its recent FDA approval for expanded access, which comes after clinical trials showed it can double survival rates in advanced cases of the disease. #CancerResearch #FDAApproval #PancreaticCancer #US

U.S. cancer centers are urgently enrolling patients in an expanded access program for the promising pancreatic cancer drug daraxonrasib, which recently showed in clinical trials to significantly extend survival, while they await expected FDA approval amidst a surge of patient requests. #CancerResearch #FDAApproval #PancreaticCancer #US